Numab Innovation

Executive Summary

Numab Innovation (Numab Therapeutics AG) is a Swiss biotechnology company pioneering next-generation multispecific antibody-based therapeutics using its proprietary λ-Cap™ and MATCH™ platforms. Founded in 2011 and headquartered in Zurich, the company focuses on developing novel biologics for cancer and inflammatory diseases. Numab's plug-and-play platform enables rapid assembly of stable, multispecific antibodies with desirable drug-like properties, offering potential advantages over conventional formats. As a private, pre-clinical stage company, Numab is strategically advancing an internal pipeline while pursuing discovery and development partnerships with pharmaceutical companies to leverage its technology across multiple targets. The company's innovative approach positions it to address complex diseases, but it remains in early-stage development with no disclosed pipeline candidates or clinical data. Numab's success hinges on advancing its lead programs toward clinical trials and securing partnerships to validate its platforms.

Upcoming Catalysts (preview)

• Q3 2026Lead Program IND Filing40% success
• Q4 2026Major Pharma Partnership for λ-Cap/MATCH Platform35% success
• Q3 2026Preclinical Data Presentation at Major Conference60% success